您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2014, Vol. 52 ›› Issue (8): 22-26.doi: 10.6040/j.issn.1671-7554.0.2014.041

• 基础医学 • 上一篇    下一篇

甲状旁腺激素对骨质疏松种植体骨结合的影响

狄婧1, 石晓婷2, 李雪3, 林志勇1, 孙哲1, 邓凤英1   

  1. 1. 山东大学附属省立医院口腔内科, 山东 济南 250021;
    2. 天津市口腔医院儿童口腔科, 天津 300041;
    3. 山东医学高等专科学校口腔医学系, 山东 济南 250014
  • 收稿日期:2014-01-15 修回日期:2014-06-10 出版日期:2014-08-10 发布日期:2014-08-10
  • 通讯作者: 林志勇。E-mail：zhiyongl@126.com E-mail:zhiyongl@126.com
  • 基金资助:
    山东省科技发展基金资助项目（2010G0020226）

Effect of parathyroid hormone1-34 on bone healing around dental implants in ostoeporotic rats

DI Jing1, SHI Xiaoting2, LI Xue3, LIN Zhiyong1, SUN Zhe1, DENG Fengying1   

  1. 1. Department of Oral Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China;
    2. Department of Pediatric Dentistry, Tianjin Stomatological Hospital, Tianjin 300041, China;
    3. Department of Stomatology, Shandong Medical College, Jinan 250014, Shandong, China
  • Received:2014-01-15 Revised:2014-06-10 Online:2014-08-10 Published:2014-08-10

PDF (PC)

163

摘要： 目的 研究甲状旁腺激素（PTH1-34）对骨质疏松种植体骨结合的影响。方法 36只雌性Wistar大鼠随机分为假手术组、去势组和去势加PTH1-34治疗组，每组12只。假手术组接受假手术，去势组和去势加PTH1-34治疗组行双侧卵巢切除术。术后8周测量胫骨骨密度，证实骨质疏松状态。同时在3组大鼠右侧胫骨近干骺端分别植入纯钛螺纹柱状种植体，假手术组和去势组用生理盐水1 mL/kg，去势加PTH1-34治疗组用PTH1-3420 μg/kg，隔日腹腔注射1次，用药8周。种植术用药4、8周后处死各组半数大鼠，标本制作带种植体的骨组织磨片，行组织学观察及骨计量学测量。结果 种植术后第4周，去势加PTH1-34治疗组骨小梁平均宽度、种植体骨结合率和结合骨板宽度均显著高于去势组（P<0.05），而去势加PTH1-34治疗组种植体骨结合率与假手术组相比，差异无统计学意义（P>0.05）。种植术后第8周，去势加PTH1-34治疗组松质骨区骨量、骨小梁平均宽度、种植体骨结合率和结合骨板宽度较去势组均有明显提高（P<0.05），与假手术组相比，差异无统计学意义（P>0.05）。结论 骨质疏松对种植界面早期骨结合有一定的影响，间歇性、小剂量注射PTH1-34可有效促进骨形成，从而提高种植体骨结合的质量。

关键词: 骨质疏松, 骨结合, 种植体, 甲状旁腺激素

Abstract: Objective To investigate the effect of parathyroid hormone1-34 (PTH1-34) on bone healing around dental implants in ostoeporotic rats. Methods A total of 36 female Wistar rats were randomly divided into the sham-operation group, ovariectomized group and ovariectomized with PTH1-34 treatment group, with 12 in each group. Animals in the sham-operation group underwent sham-operation, while rats in ovariectomized group and ovariectomized with PTH1-34 treatment group received bilateral ovariectomy. Eight weeks after surgery, tibia of rats was examined for bone mineral density to verify osteoporosis status. At the same time, Pure screw titanium implant was placed in the right tibia near metaphysis. Every other day for 8 weeks, normal saline 1 mL/kg was intraperitoneally injected in rats in sham-operation group and ovariectomized group, while PTH1-34 20 μg/kg in rats in the ovariectomized with PTH1-34 treatment group. In week 4 and 8 after implantation surgery, half of the rats in each group were killed. Undecalcified sections were preparedand examined histologically and histomorphometrically. Results In week 4, the trabercular width (TW), implant bone contact rate (IBCR), combinded bone lamella width (CBLW) of rats in ovariectomized with PTH1-34 treatment group were much higher than those of rats in ovariectomized group (P<0.05). In terms of IBCR, there was no difference between ovariectomized with PTH1-34 treatment group and sham-operation group (P>0.05). In week 8, trabercular area (TA), TW, IBCR and CBLW were significantly elevated in ovariectomized with PTH1-34 treatment group when compared with ovariectomized group (P<0.05). There was no difference between ovariectomized with PTH1-34 treatment group and sham-operation group in all parameters (P>0.05). Conclusion Osteoporosis impedes osseointegration in ovariectomized rats. Intermittent application of parathyroid hormone1-34 with small doses can promote bone formation effectively to improve the osseointegration quality of rats.

Key words: Osteoporosis, Parathyroid hormone, Dental implants, Osseointegration

中图分类号: 

  • R782.1
[1] Keller J C, Stewart M, Roehm M, et al. Osteoporosis-like bone conditions affect osseointegration of implants[J]. Int J Oral Maxillofac Implants, 2004, 19(5):687-694.
[2] Hwang D, Wang H L. Medical contraindications to implant therapy PartII: Relative contraindications[J]. Implant Dent, 2007, 16(1):13-23.
[3] Beppu K, Kido H, Watazu A, et al. Peri-implant bone density in senile osteoporosis-changes from implant placement to osseointegration[J]. Clin Implant Dent Relat Res, 2013, 15 (2):217-226.
[4] Qi M C, Zhou X Q, Hu J, et al. Oestrogen replacement therapy promotes bone healing around dental implants in osteoporotic rats[J]. Int J Oral Maxillofac Surg, 2004, 33(3):279-285.
[5] 朱显军, 张学军, 李蓬秋, 等. 重组人甲状旁腺素(1-34)对绝经后骨质疏松症的治疗作用研究[J]. 四川医学, 2011, 32(7):1020-1023.
[6] Pettway G J, Meganck J A, Koh A J, et al. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation[J]. Bone, 2008, 42(4):806-818.
[7] Syed F, Khosla S. Mechanisms of sex steroid effects on bone[J]. Biochem Biophys Res Commun, 2005, 328(3):688-696.
[8] Amorim M A, Takayama L, Jorgetti V, et al. Comparative study of axial and femoral bone mineral density and parameters of mandibular bone quality in patients receiving dental implants[J]. Chteoporos, 2007, 18(5):703-709.
[9] Dvorak G, Arnhart C, Heuberer S, et al. Peri-implantitis and late implant failures in postmenopausal women: a cross-sectional study[J]. J Clin Periodontol, 2011, 38(10):950-955.
[10] Zhang X Z, Wang B, Yang J, et al. A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China[J]. Chin Med J, 2009, 122(24):103-115.
[11] Alkhiary Y M, Gerstenfeld L C, Krall E, et al. Enhancement of ex-perimental fracture-healing by systemic administration of recombinant human parathyroid hormone (1-34)[J]. Bone Joint Surg Am, 2005, 87(4):731-741.
[12] Guo Y S, Yuan W J, Zhang A P, et al. Parathyroid hormone-mitogen-activated protein kinase axis exerts fibrogenic effect of connective tissue growth factor on human renal proximal tubular cells[J]. Chin Med J, 2010,123(24):273-277.
[13] 于志峰, 金慰芳, 顾淑珠, 等. rhPTH(1-34)治疗OVX大鼠骨质疏松延后效应的初步研究[J]. 中国骨质疏松杂志, 2005, 11(2):278-280.
[14] Cosman F, Lane N E, Bolognese M A, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women[J]. JCEM, 2010, 95(1):151-158.
[15] Gabet Y, Muller R, Levy J, et al. Parathyroid hormone1-34 enhances titanium implant anchorage in low-density trabecular bone: a correlative micro-computed tomographic and biomechanical analysis[J]. Bone, 2006, 39(2):276-282.
[16] Skripitz R, Johansson H R, Ulrich S D, et al. Effect of alendronate and intermittent parathyroid hormone on implant fixation in ovariectomized rats[J]. J Orthop Sci, 2009, 14(2):138-143.
[17] 李裕明, 邓波. 甲状旁腺激素在骨质疏松症治疗中的作用[J]. 临床内科杂志, 2009, 26(3):152-154.
[1] 刘凯林,郭莹,王志昊,耿冲,王娜娜. 基础生理指标对甲状旁腺功能的影响[J]. 山东大学学报 (医学版), 2025, 63(6): 100-106.
[2] 杨浩然,刘青,徐力群,张盼盼,姜涛. 应用引导组织再生术及植骨术治疗种植体周围炎1例[J]. 山东大学学报 (医学版), 2024, 62(4): 101-107.
[3] 王璐瑶,胡晓琳,孙佩,董振华,逄曙光. 青年合并骨质疏松的Gitelman综合征1例[J]. 山东大学学报 (医学版), 2024, 62(2): 120-124.
[4] 朱超,孙超,刘绪昌,夏大伟,马春骋,丰荣杰. 3D打印椎间融合器在37例单节段腰椎手术中的应用[J]. 山东大学学报 (医学版), 2023, 61(3): 134-140.
[5] 陈诗鸿,姜冬青,庄向华,李晓博,潘喆,孙爱丽,娄能俊,王殿辉,杜娇娇,宋玉文. 以骨痛为首发表现的原发性胆汁性胆管炎1例[J]. 山东大学学报 (医学版), 2022, 60(8): 98-102.
[6] 吕丽,姜璐,陈诗鸿,庄向华,宋玉文,王殿辉,安文娟,李倩,潘喆. 210例绝经后2型糖尿病发生骨质疏松的相关因素[J]. 山东大学学报 (医学版), 2021, 59(7): 19-25.
[7] 陈诗鸿. 糖皮质激素性骨质疏松症研究进展[J]. 山东大学学报 (医学版), 2021, 59(6): 33-37.
[8] 程晓光,卢艳慧. 男性骨质疏松:一个长期被忽视的问题[J]. 山东大学学报 (医学版), 2021, 59(6): 5-9.
[9] 罗湘杭,周若玙. 骨质疏松的病因及发病机制研究进展[J]. 山东大学学报 (医学版), 2021, 59(6): 10-14.
[10] 李敏启,杜娟,杨盼盼,寇雨莹,柳珊珊. 氧化应激调控骨质疏松症的研究进展[J]. 山东大学学报 (医学版), 2021, 59(6): 16-24.
[11] 杜娇娇,庄向华,陈诗鸿,王雪萌,姜冬青,吴菲,韩晓琳,华梦羽,宋玉文. 绝经后骨质疏松症患者血清IL-31、IL-33表达变化[J]. 山东大学学报 (医学版), 2021, 59(6): 45-50.
[12] 刘萍,宋玉文,王萍,田光伟,郑凤杰,吕丽,杜娇娇,张静,庄向华,陈诗鸿. 维生素D缺乏与2型糖尿病合并抑郁状态的相关性[J]. 山东大学学报 (医学版), 2021, 59(6): 51-56.
[13] 邢小平. 原发性骨质疏松症诊治思考[J]. 山东大学学报 (医学版), 2021, 59(6): 1-4.
[14] 康成为,刘雷,蒲小兵,谭钢,董长超,晏兆魁. 合并亚临床型甲状腺功能减退的骨质疏松症62例患者骨代谢及骨转换标志物水平分析[J]. 山东大学学报 (医学版), 2020, 58(5): 82-86.
[15] 李源,王强,石晓蕾,张晓丽,徐欣. 卷曲受体蛋白4在高脂血症大鼠种植体周围组织中的早期表达[J]. 山东大学学报 (医学版), 2020, 58(2): 29-35.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发